Science Corp and Neurosoft unite to speed brain-computer care
Science Corporation and Neurosoft Bioelectronics announced a partnership to combine Neurosoft’s soft neural implants with Science’s full-stack BCI platform to speed clinical development of brain-computer interface therapies. The deal aims to lower infrastructure costs for first-in-human trials from an estimated $75–100 million to under $5 million, leveraging Neurosoft devices (tested in about a dozen patients) and AI-trained neural data for indications including tinnitus and epilepsy.
Why it mattersCost reduction from $75–100M to under $5M enables faster first-in-human BCI trials and investment decisions.
Entities Mentioned
Science CorporationNeurosoft Bioelectronics
People Mentioned
Kyle Umipig